Statins are lipid-lowing medications shown to reduce cardiovascular events and are recommended for specific patient populations at elevated risk of atherosclerotic cardiovascular disease (ASCVD). Despite the demonstrated efficacy of statins for reducing ASCVD risk, and guidance on which populations should receive statin therapy, a substantial portion of eligible patients are not prescribed statin therapy. Pharmacists have attempted to increase the number of eligible patients receiving appropriate statin therapy through a variety of interventions and across several clinical settings. In this article, we highlight multiple studies evaluating the effectiveness of pharmacist-led interventions to improve statin use. A total of seven studies were...
Ample evidence supports the use of statin therapy for secondary prevention in patients with a histor...
Item does not contain fulltextBACKGROUND: Although statins have indisputably proven to reduce fatal ...
Purpose of review: Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in parti...
Statins are lipid-lowing medications shown to reduce cardiovascular events and are recommended for s...
Statins are lipid-lowing medications shown to reduce cardiovascular events and are recommended for s...
Clinical Pharmacist-Led Intervention to Improve Statin Metric for Secondary Prevention at Providence...
Clinical Pharmacist-Led Intervention to Improve Statin Metric for Secondary Prevention at Providence...
<div><p>Background</p><p>Small trials with short term follow up suggest pharmacists’ interventions t...
Background: Small trials with short term follow up suggest pharmacists’ interventions targeted at...
Small trials with short term follow up suggest pharmacists’ interventions targeted at healthcare pro...
Background: Small trials with short term follow up suggest pharmacists ’ interventions targeted at h...
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. BACKGROUND ...
Statins clearly confer substantial benefit in people with established cardiovascular (CV) disease. I...
BACKGROUND: The Statin Use in Persons with Diabetes (SUPD) measure, developed and endorsed by the Ph...
Ample evidence supports the use of statin therapy for secondary prevention in patients with a histor...
Ample evidence supports the use of statin therapy for secondary prevention in patients with a histor...
Item does not contain fulltextBACKGROUND: Although statins have indisputably proven to reduce fatal ...
Purpose of review: Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in parti...
Statins are lipid-lowing medications shown to reduce cardiovascular events and are recommended for s...
Statins are lipid-lowing medications shown to reduce cardiovascular events and are recommended for s...
Clinical Pharmacist-Led Intervention to Improve Statin Metric for Secondary Prevention at Providence...
Clinical Pharmacist-Led Intervention to Improve Statin Metric for Secondary Prevention at Providence...
<div><p>Background</p><p>Small trials with short term follow up suggest pharmacists’ interventions t...
Background: Small trials with short term follow up suggest pharmacists’ interventions targeted at...
Small trials with short term follow up suggest pharmacists’ interventions targeted at healthcare pro...
Background: Small trials with short term follow up suggest pharmacists ’ interventions targeted at h...
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. BACKGROUND ...
Statins clearly confer substantial benefit in people with established cardiovascular (CV) disease. I...
BACKGROUND: The Statin Use in Persons with Diabetes (SUPD) measure, developed and endorsed by the Ph...
Ample evidence supports the use of statin therapy for secondary prevention in patients with a histor...
Ample evidence supports the use of statin therapy for secondary prevention in patients with a histor...
Item does not contain fulltextBACKGROUND: Although statins have indisputably proven to reduce fatal ...
Purpose of review: Dyslipidaemias are a major risk factor for cardiovascular disease (CVD); in parti...